Astrazeneca Pharma India Ltd (ASTRAZEN) is currently trading at 6,383.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

AstraZeneca Pharma India Limited is the Indian subsidiary of AstraZeneca PLC that manufactures, markets and distributes prescription pharmaceutical products across oncology, cardio‑metabolic, respiratory, renal and rare disease therapy areas, while coordinating clinical trial services and acting as the commercial vehicle for multiple global AstraZeneca launches in India. Reported unaudited results for the quarter ended 31 December 2025 show total income of Rs. 6,167.0 lakhs and profit after tax of Rs. 325.9 lakhs; quarter revenue reflects a year‑on‑year increase versus the prior corresponding period based on reported figures, while PAT rose more modestly, indicating margin and mix effects on quarterly profitability. Management has announced cessation of operations at the Bangalore manufacturing site and is actively pursuing sale of the associated assets, indicating a strategic shift away from local manufacturing operations toward asset monetization and outsourcing or reliance on third‑party manufacturing arrangements for supply continuity. The company has been an active launcher of novel therapies and biologics in India in recent years — including Enhertu, Lynparza, Fasenra, Breztri and Soliris — and secured indication extensions for oncology agents, creating a pipeline of high‑value specialty products that underpin medium‑term commercial growth potential. AstraZeneca Pharma India has historically used strategic partnerships and global corporate actions to expand its marketed portfolio, such as distribution/co‑promotion agreements with Indian majors and the global acquisition of BMS diabetes assets, which materially increased its diabetes offerings and commercial reach in India.

Over the past 52 weeks, Astrazeneca Pharma India Ltd has traded between a low of ₹5,660.00 and a high of ₹9,850.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Astrazeneca Pharma India Ltd has a market capitalization of approximately 15,745.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Astrazeneca Pharma India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 92.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15,745.13 Cr, Astrazeneca Pharma India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Astrazeneca Pharma India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Astrazeneca Pharma India Ltd is 92.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company reported FY 2025-26 total revenue from operations of INR 22,755.8 million for the year ended 31 March 2026.

NPPA has demanded ₹148.66 crore, inclusive of interest, in relation to Symbicort Turbuhaler 160/4.5 (Inhaler).

The company said CDSCO approved Enhertu for an additional indication, allowing it to import, sell and distribute the drug in India for expanded use.

In the provided quarterly table, net income for Mar’25 is ₹58.25 crore and total revenue is ₹480.48 crore.